Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05429372 |
| Consolidated Lead Sponsor | Pfizer |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 10 participants (ACTUAL) |
| Registered Start Date | 2022-08-08 |
| WhyStopped Classification | Safety / Toxicity / Adverse Events |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| University of Florida | Gainesville, FL | Open Hospital Dossier -> |
| Children's Hospital of Philadelphia | Philadelphia, PA | Open Hospital Dossier -> |
| Huntsman Cancer Institute at University of Utah | Salt Lake City, UT | Open Hospital Dossier -> |
| Primary Children's Hospital | Salt Lake City, UT | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.